MétaCan
Menu
Back to cohort
Record W4405263852 · doi:10.1016/j.cjca.2024.09.014

Can the Present Canadian Health Care System Provide Evidence-Based Pharmaceutical Care? Consideration of Two Important Cardiovascular Clinical Contexts

2024· article· en· W4405263852 on OpenAlexaffvenueabout
Morgane Laverdure, Cole Clifford, Quinton Barry, William Knoll, Rene Boudreau, Marie Lordkipanidzé, Jean‐François Tanguay, Aun‐Yeong Chong, Derek So

Bibliographic record

VenueCanadian Journal of Cardiology · 2024
Typearticle
Languageen
FieldMedicine
TopicClinical practice guidelines implementation
Canadian institutionsUniversité de MontréalUniversity of TorontoMontreal Heart InstituteUniversity of Ottawa
Fundersnot available
KeywordsMedicinePharmaceutical careHealth careHealthcare systemAlternative medicineFamily medicineIntensive care medicineEconomic growthPathology

Abstract

fetched live from OpenAlex

BACKGROUND: Canada is the only country with universal health care lacking universal pharmaceutical care (pharmacare). Currently, a minority portion of the population has drug coverage. Furthermore, there may be discordance between provincial plans of medications that are covered. We aimed to evaluate present systems for drug coverage and ability to provide evidence-based care according to Canadian cardiovascular (CV) guidelines. METHODS: The drug review process and formularies for provinces and territories were queried to evaluate concordance between guideline-recommended medications and present coverage. Two common cardiology scenarios, heart failure with reduced ejection fraction and antiplatelet drugs in acute coronary syndrome, were chosen as case studies because of recent Canadian-based CV practice guideline updates. Coverage criteria were extracted to assess for interprovincial variations and determine whether listing decisions are concordant with best evidence and guidelines. RESULTS: Multiple organisations are involved in drug review. Despite Canada's Drug and Health Technology Agency (CADTH) recommendations, there are extensive interprovincial variations in listing decisions for CV drugs, with CADTH recommendations followed only 33% of the time. Among 24 CV drugs reviewed, 23% of listing decisions were discordant from guidelines and best evidence. Novel drugs disproportionately carried the highest discordance from evidence. No systematic process exists for formulary updates based on new evidence, changes in guidelines, or drug pricing. CONCLUSIONS: Current Canadian drug review decisions are complex and coverage decisions vary widely, resulting in an inability to provide guideline-recommended CV evidence-based medicine. In developing future pharmacare programs, it is crucial to centralise the drug review process and integrate mechanisms to incorporate up-to-date evidence.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.036
metaresearch head score (Gemma)0.187
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Evaluation · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.964
Threshold uncertainty score0.801

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0360.187
Meta-epidemiology (narrow)0.0000.001
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0090.015
Science and technology studies0.0120.007
Scholarly communication0.0160.006
Open science0.0040.005
Research integrity0.0030.003
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.268
GPT teacher head0.502
Teacher spread0.234 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designObservational
DomainEvaluation
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2024
Admission routes3
Has abstractyes

Explore more

Same venueCanadian Journal of CardiologySame topicClinical practice guidelines implementationFrench-language works237,207